Cardioxyl Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery and development of new classes of therapeutic agents for cardiovascular disease. The company’s core HNO (nitroxyl) platform has produced several pre-clinical and clinical candidates. Cardioxyl is advancing second-generation HNO donor programs intended to treat acute and chronic heart failure. The company is led by President and CEO Chris Kroeger, M.D. It intends to use newly raised capital to further advance those second-generation HNO programs. Cardioxyl is based in Chapel Hill, North Carolina. Cardioxyl Pharmaceuticals is a clinical-stage pharmaceutical company developing novel therapeutic agents for the treatment of cardiovascular disease. The company is based in Chapel Hill, NC. Its lead drug candidate is CXL-1020, being developed for acute decompensated heart failure (ADHF). Cardioxyl reported positive safety and tolerability results in the first clinical study of CXL-1020. The company raised an additional $15 million to execute a Phase IIa trial of CXL-1020 and to continue development of its research portfolio. Investors in the funding include existing backers Aurora Funds and New Enterprise Associates (NEA).

Total raised

$43M

Funding rounds

2

Latest round

Series B

Latest activity

Nov 2012